Targacept Inc. and AstraZeneca have enrolled the first patient in a Phase III program for depression drug candidate TC-5214, which showed positive results in Phase II testing as an add-on therapy for patients who did not respond well to prior treatment with another antidepressant, citalopram. (BioWorld Today)